Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Loser

Vertex Pharmaceuticals ( VRTX) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.9%. By the end of trading, Vertex Pharmaceuticals fell $1.15 (-2.1%) to $52.40 on light volume. Throughout the day, two million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 4.2 million shares. The stock ranged in price between $51.56-$53.71 after having opened the day at $52.65 as compared to the previous trading day's close of $53.55. Other company's within the Drugs industry that declined today were: Allos Therapeutics ( ALTH), down 20.1%, K-V Pharmaceutical Company ( KV.A), down 12.3%, Cormedix ( CRMD), down 11.9%, and Amyris ( AMRS), down 11%.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $11.17 billion and is part of the health care sector. The company has a P/E ratio of 36.5, below the average drugs industry P/E ratio of 38.6 and above the S&P 500 P/E ratio of 17.7. Shares are up 59.4% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Anthera Pharmaceuticals ( ANTH), up 87.2%, Alnylam Pharmaceuticals ( ALNY), up 53%, Par Pharmaceutical Companies ( PRX), up 36.7%, and iBio ( IBIO), up 31.3%, were all gainers within the drugs industry with Sanofi ( SNY) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level

Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Trump Threatens More Tariffs and 4 Other Stories to Watch Tuesday Morning

Trump Threatens More Tariffs and 4 Other Stories to Watch Tuesday Morning

Trump Issues New Trade Threats, Apple, ZTE, GameStop - 5 Things You Must Know

Trump Issues New Trade Threats, Apple, ZTE, GameStop - 5 Things You Must Know

China-Focused Stocks Hit Hard as Beijing Responds to Trump Tariff Threats

China-Focused Stocks Hit Hard as Beijing Responds to Trump Tariff Threats